Moloney Securities Asset Management’s Lipocine LPCN Stock Holding History

Moloney Securities Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,324	Closed	-$7.16K	–	443
2023 Q1	$7.16K	Hold	1,324	–	–	﹤0.01%	416
2022 Q4	$8.95K	Hold	1,324	–	–	﹤0.01%	385
2022 Q3	$10K	Hold	1,324	–	–	﹤0.01%	367
2022 Q2	$18K	Hold	1,324	–	–	﹤0.01%	356
2022 Q1	$31K	Hold	1,324	–	–	0.01%	394
2021 Q4	$22K	Sell	1,324 -441	-25%	-$8.19K	﹤0.01%	430
2021 Q3	$33K	Hold	1,765	–	–	0.01%	423
2021 Q2	$42K	Buy	+1,765	New	+$41.5K	0.01%	419

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Moloney Securities Asset Management's LPCN Position: Q2 2023 in Review

Moloney Securities Asset Management sold out of Lipocine (LPCN) in Q2 2023, closing a stake of 1,324 shares — an estimated $7.16K sold.

Moloney Securities Asset Management first reported a position in LPCN in Q2 2021 and held it in 8 quarters. The position peaked at $42K in Q2 2021. 24 funds tracked by Wall St. Rank hold LPCN as of Q2 2023.

Moloney Securities Asset Management reported no remaining Lipocine position as of Q2 2023 after selling out during the quarter.
Moloney Securities Asset Management sold 1,324 Lipocine shares in Q2 2023, an estimated $7.16K.
Moloney Securities Asset Management first reported a position in Lipocine in Q2 2021 and held it in 8 quarters.
Moloney Securities Asset Management's Lipocine position peaked at $42K in Q2 2021.
24 funds tracked by Wall St. Rank held Lipocine as of Q2 2023.

Based on Moloney Securities Asset Management's 13F filing for Q2 2023, filed 31 Jul 2023.